References
- Arora A, Scholar EM. Role of Tyrosine Kinase Inhibitors in Cancer Therpy. J Pharmachol Exp Ther 2005; 315(3): 971-9. https://doi.org/10.1124/jpet.105.084145
- Steeghs N, Nortier JW, Gelderblom H. Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments. Ann Surg Oncol 2007; 14(2): 942-53. https://doi.org/10.1245/s10434-006-9227-1
- Capizzi RL, Keiser LW, Sartorelli AC. Combination Chemotherapy-theory and practice. Semin Oncol 1977; 4(2): 227-53.
- Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer 2006; 6(7):546-58. https://doi.org/10.1038/nrc1887
- Van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009; 35(8): 692-706. https://doi.org/10.1016/j.ctrv.2009.08.004
- 홍경자, 이석용. 약물상호작용의 이해. 2003, 신일상사
- Hartmann JT, Haap M, Kopp HG, et al., Clinical pharmacokinetics of tyrosine kinase inhibitors. Curr Drug Metab 2009; 10: 470-81. https://doi.org/10.2174/138920009788897975
- Tanaka C, Yin OQ, Smith T, Sethuraman V, Grouss K, Galitz L, Harrell R, Schran H. 2011 "Effect of Rifampin and Ketoconazole on the pharmacokinetics of nilitinib in healthy participants." J Clin Pharmacol 51(1): 75-83. https://doi.org/10.1177/0091270010367428
- van Leeuwen, Swart EL, Boven E, et al., Potential drug interaction in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol 2011; 22: 2334-41. https://doi.org/10.1093/annonc/mdq761
- Guastaldi RB, Resi AM, Figueras A, Secoli SR. 2011 "Prevalence of potential drug-drug interactions in bone marrow transplant patients." Int J Clin Pharm 33(6): 1002-9. https://doi.org/10.1007/s11096-011-9574-2
- World Health Organization. Collaborating Center for Drug Statistics Methodology. ATC/DDD Index 2012. http:// www.whocc.no/atcddd/index. (accessed on May 1, 2012)
- Thompson Reuters Micromedex(R)2.0. http://www.thomsonhc. com/micormedex2 .(Accessed on May 1, 2012)
- Lexi-interact TM Online. http://www/uptodate.com/crlsql/ interact/fra,eset.jsp .(Accessed on May 1, 2012)
- Ogawa R, Echizen H. Clinically significant drug interactions with antacid: an update. Drugs 2011; 71: 1839-64. https://doi.org/10.2165/11593990-000000000-00000
- Eley T, Luo FR, Agrawal S, et al., Phase 1 study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol 2009; 49: 700-9. https://doi.org/10.1177/0091270009333854
- Sparano BA, Egorin MJ, Parise RA, et al., Effect of antacid on imatinib absorption. Cancer Chemother Pharmacol 2009; 63: 525-8. https://doi.org/10.1007/s00280-008-0778-7
- Tarceva prescribing information. Genetech, http://gene.com/ gene/products/information/oncology/tarceva. (Accessed on May 1, 2012).
- Iressa product information. Astrazeneca. http://www.iressa.com/product-information. (Accessed on May 3, 2012).
- Writht A, Feblowitz J, Phansalkar S, et al., Preventability of adverse drug events involving multiple drugs using publicly available clinical decision support tools. Am J Health Syst Pharm 2012; 69: 221-7. https://doi.org/10.2146/ajhp110084
- Midyear Clinical Meeting supplemental handout. ASHP 2009. Drug Interaction Alerts: The Battle against alert fatigue. http://www.ashp.org/DocLibrary/MemberCenter/ SPPM/ManagePearls/MCM09-223-16-Handout-Lee.aspx. (Accessed on May 3, 2012).
- ASHP Guidelines on Medication-Use-Evaluation. 1996. http://www.ashp.org/DocLibrary/BestPractices/FormGdlmed UseEval.aspx (Accessed on May 1, 2012).
- Moura CS, Prado NM, Belo NO, et al., Evaluation of drugdrug interaction screening software combined with pharmacist intervention. Int J Clin Pharm 2012; (DOI:10.1007/s11096-012-9642-2).
- Hartmann JT, Happ M, Kopp HG, et al., Tyrosine Kinase Inhibitors-A Review on Pharmacology, Metabolism and Side Effects. Curr Drug Metab 2009; 10: 470-81. https://doi.org/10.2174/138920009788897975
- Gleevec product information. Norvatis. http://www.gleevec. com/health-care-professional. (Accessed on May 3, 2012).
- Tykerb product information. GSK. http://www.tykerb.com (Accessed on May 3, 2012).
- Nexavar product information. Bayer. http://www.nexavarinternational. com/home/important_safety_considerations,php. (Accessed on May 1, 2012).
- Sutent prescribing information. Pfizer. http://www.pfizer. com/files/products/uspi_sutent/pdf (Accessed on May 1, 2012).